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Quinidine Trial in a Patient with Epilepsy of Infancy with 
Migrating Focal Seizure and KCNT1 Mutation
Epilepsy of infancy with migrating focal seizure (MFEI) is an early-onset epileptic 
encephalopathy characterized by randomly migrating focal seizures and 
psychomotor deterioration. It is associated with mutations in a variety of genes, 
with potassium sodium-activated channel subfamily T member 1 (KCNT1) being 
an example. Previously reported KCNT1 mutations in MFEI are gain-of-function 
mutations. Therefore, quinidine therapy targeted at reduction of pathologically 
increased KCNT1 channel-mediated potassium conductance has been proposed as a 
target treatment for MEFI with KCNT1 mutation. The authors report a case involving 
a patient with MFEI and a missense mutation in KCNT1 (c.7129G>A; p.Phe346Leu) 
treated with quinidine therapy. Seizure activity was poorly responsive to quinidine. 
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Introduction
Epilepsy of infancy with migrating focal seizures (MFEI) is a rare, early onset 
epileptic encephalopathy characterized by pharmacoresistant epilepsy and arrest 
of psychomotor development in the first 6 months of life1-4). Interictal electro-
encephalography (EEG) demonstrates multifocal spikes and slowing, with ictal 
EEG discharges arising from various areas of both hemispheres and migrating 
from one brain region to another. 
Several genetic causes of MFEI have been identified, including mutations in the 
potassium sodium-activated channel subfamily T member 1 (KCNT1)5), 
phospholipase C beta 1 (PLCB1)6), sodium voltage-gated channel alpha subunit1 
(SCN1A)7), solute carrier family 25 member 22 (SLC25A22)6), and TBC1 domain 
family member 24 (TBC1D24)8). More recently, de novo mutations in the KCNT1 
gene (also known as Slo2.2 or Slack) were described as disease-causing in 
approximately 40% to 50% of all MFEI patients5,9,10). Mutations result in KCNT1 
channel gain of function. Importantly, reported KCNT1 mutations in MFEI are 
gain-of-function mutations leading to constitutive activation of the channel; 
therefore, pharmacological inhibition of KCNT1 is a potential therapeutic target5). 
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In this report, we describe a patient with MFEI and KCNT1 
mutation (c.7129G>A; p.Phe346Leu) who underwent a trial of 
quinidine.
Case report
A 3-month-old boy was admitted to our hospital via the 
emergency center for 5 generalized tonic seizures that lasted 1 
min to 2 min for 1 day. He was fitst child from nonconsangui-
neous Korean parent; He was born at fullterm and weighted 2.6 
kg. There was no family history of seizures or other neurological 
disorders. EEG demonstrated clinical and subclinical seizures 
associated with ictal discharges arising independently from the 
left frontal, left temporal, or right temporal areas. Brain magnetic 
resonance imaging revealed no abnormal findings. EEG 
demonstrated a pattern of MFEI; with focal seizures migrating 
between left and right hemispheres (Fig.1). Therefore, the 
patient was started on antiepileptic drugs (AEDs). 
Trials of multiple medications alone and in various combina-
tions, including phenobarbital, levetiracetam, phenytoin, 
topiramate, valproic acid, gabapentin, and clobazam, were 
without effect on seizure frequency, and the patient continued to 
have the patient has daily seizures of tonic seizures involving the 
left, right, or both sides of the body, 10 to 20 times a day, and 
about 1 or 2 of these seizures last longer than 20 minutes and 
required intravenous injection of benzodiazepine or other 
AEDs. When placed on continuous EEG monitoring, subclinical 
seizures were also frequently detected. A ketogenic diet was 
also attempted but was, however, abandoned after 2 months 
due to lack of efficacy. 
Metabolic and imaging work-up were negative. A gene panel 
was sent out for epileptic encephalopathy, and revealed that the 
patient had a heterozygous mutation in the KCNT1 (c.7129G>A; 
Fig. 1. Electroencephalogram at initial presentation(Ictal phase) Electroencephalogram at initial 
presentation. (A) Focal seizure originating from right temporal lobe. (B) Several seconds later, seizure has 
migrated to the left. clinically presenting as desaturation, vacant staring with eyeball fixation, 
sometimes with both arm elevation, which are associated with ictal rhythmic discharges evolving from 
Rt. temporal (10 times) or Lt. temporal (13 times) areas, and then spreading to ipsilateral diffuse 
hemisphere, sometimes speading ton whole brain.
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p.Phe346Leu). His parents were also tested; however, they did 
not carry such a mutation, confirming that the mutation of 
KCNT1 gene in the patient was a de novo mutation (Fig. 2).
After genetic diagnosis of KCNT1 encephalopathy, quinidine 
therapy was attempted. He was started on 11 mg/kg/day of 
quinidine with gradual dose increase to 54.2 mg/kg/day (320 
mg/day), but was stopped after 10 days of trial due to lack of 
response and tremor that appeared to be a side effect (Table 1).
To date, the patient (now 20 months old) experiences tonic 
seizures of either or both sides of the body 10 to 20 times per 
day, with approximately 1 or 2 of these seizures lasting longer 
than 20 min and requiring adjuvant rectal benzodiazepine 
injections in addition to 4 oral AEDs (barbiturate, levetriacetam, 
stitipentol, topiramate). The head circumference of the patient 
was normal (42 cm, 50 percentile) at the onset of disease, but 
now it is microcephaly (45 cm, <3 percentile). He has exhibited 
profound developmental regression since the onset of these 
seizures.
Discussion
We report a case involving a patient with MFEI and mutation in 
KCNT1, who demonstrated no response to quinidine therapy. 
The identification of KCNT1 mutations as a genetic cause for 
MFEI and autosomal dominant nocturnal frontal lobe epilepsy 
suggests that these conditions may be treatable using a drug that 
specifically targets the KCNT1 channel. Quinidine therapy has 
been introduced as a targeted therapy in MFEI with KCNT1 
mutation to reduce increased KCNT1 channel-mediated 
potassium conductance. KCNT1 encodes the pore-forming 
alpha subunit of the potassium channel11; quinidine acts to these 
block pores. Therefore, quinidine is a potential therapeutic agent 
for individuals with KCNT1 mutation. 
Previous studies have demonstrated that quinidine reduces 
the conductance of the activated channel by a gain-of-function 
mutation of KCNT1 in vitro12,13). Additionally, quinidine treatment 
has been trialed in three patients with KCNT1 mutations for 
whom treatment with standard antiepileptic therapies had been 
unsuccessful. Two patients with malignant migrating focal 
seizures of infancy experienced marked improvement in seizure 
control following quinidine administration. However, our patient 
did not experience the same effect as in vitro studies or other 
clinical cases. 
There are several reasons why quinidine is not effective 
against the KCNT1 mutation when applied to actual patients. The 
first is that the exact concentration of quinidine needed to be 
effective in the brain is unknown. KCNT1 is highly expressed in 
both neurons and cardiomyocytes in which quinidine acts as an 
effective antiarrhythmic agent. However, previous studies have 
shown that quinidine does not accumulate well in the 
cerebrospinal fluid, and that levels change with interactions with 
AEDs14,15). Thus, quinidine levels in the brains of patients taking 
AEDs may be lower than serum levels of those taking it to treat 
arrhythmias. However, it remains unclear whether quinidine can 
pass the blood-brain barrier and what levels are effective once it 
Fig. 2. Sequence chromatogram and alignment to the reference sequence 
revealing variation. KCNT1 (likely pathogenic), a missense mutation that 
was not previously reported was observed as a heterozygote, and a family 
test was performed. The mutation was not detected in the parent sample 
and was confirmed as a de novo mutation. A mutation that has not been 
reported so far or is not reported in the normal population, and the KCNT1 
is a de novo mutation in the autosomal dominent genetic pattern in 
epileptic encephalotpathy, which may be a genetic cause in this patient.
Table 1. Timeline of Treatment
Quinidine dose Quinidine level Seizures/day
Day 1-3 11 mg/kg/day 0.6 µg/mL 10
Day 4-6 40 mg/kg/day 2.4 µg/mL 13
Day 7-10 54.2 mg/kg/day 1.7 µg/mL 8
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has reached the brain. QT prolongation may occur due to the 
side effects of quinidine, which makes it difficult to determine 
an appropriate level because quinidine cannot be tried in 
unlimited doses until it becomes effective. Second, MFEI patients 
with KCNT1 mutations who undergo quinidine trials have 
already failed many conventional AEDs. Most are taking multiple 
AEDs, which can also affect quinidine levels. In addition, 
because seizures have been intractable for a certain period of 
time, it is likely that morphological changes have already 
occurred in the brain, regardless of the presence of KCNT1 
mutation16). Third, because phenotype and genotype are not 
always consistent, unlike previous reports describing the 
effectiveness of quinidine for MFEI, it may not have been 
effective in our patient. It is necessary to confirm that the 
treatment for the mutation in the genotype applies to the 
phenotype. 
The isolation of human induced pluripotent stem cells (iPSCs) 
offers a novel strategy for modeling human disease, recent 
studies have reported the derivation and differentiation of 
disease-specific human iPSCs. Therefore, iPSCs may represent a 
possible investigative avenue in this disease model17,18). It is also 
possible to perform experiments in an animal-based model with 
KCNT1 using gene editing through clustered regularly interspa-
ced short palindromic repeat (CRISPR)-Cas9 (CRISPR associated 
protein 9) technology19,20).
Seizure frequency in our patient was not decreased by quini-
dine therapy. In conclusion, this case suggests that quinidine is 
not always an effective treatment for individuals with epilepsy of 
infancy with migrating focal seizures and KCNT1 mutation. To 
tailor therapy to genetic mutations in patients, therefore, it will 
be necessary to conduct preliminary studies on how genotypes 
are actually expressed as phenotypes. Further studies are 
necessary to investigate exact effective doses and serum levels 
for the use of quinidine in patients with KCNT1 mutation, and to 
study whether the effect will be different when using pre-
emptive targeting agents in addition to conventional AEDs.
요약
영아이동성 부분 발작 뇌전증(MEFI)은 여러 부위에 무작위적으로 
발생하는 이동성 부분 발작과 발달이상을 특징으로 하는 조기 발병 
뇌증이다. 이는 다양한 유전자의 돌연변이와 연관되어있고 그 중 하나
로 KCNT1 돌연변이가 있다. 이전 연구에 따르며 MEFI의 KCNT1 돌
연변이는 기능획득 돌연변이로 알려져 있다. 따라서 KCNT1 돌연변이
를 가진 MEFI 환자의 표적 치료로서 병적으로 증가 된 KCNT1 채널 
매개 칼륨 전도성의 감소를 일으키는 퀴니딘 치료가 제안되었다. 이 
증례에서는 KCNT1 유전자에 결실 돌연변이(c.7129G → A; p.
Phe346Leu)가 MEFI 있는 환자에게 퀴니딘 치료를 시도하여 보고하
는 바이다. 특이 출생력 과거력 및 가족력없는 환아로 생후 3개월에 
발생한 전신 긴장성 발작을 주소로 내원하였다. 시행한 뇌파에서 왼
쪽 후두엽, 오른쪽 후두엽 및 왼쪽 전두엽 부위에서 이동성으로 편측
뇌에서 발생하는 간질파 양상을 보여 영아이동성 부분 발작 뇌전증으
로 진단되었으며 phenobarbital, levetiracetam, phenytoin, 
topiramate, valproic acid, gabapentin, clobazam 등의 AED를 사
용하였으나 발작빈도에 변화가 보이지 않았으며 케톤생성식이를 2달
간 시도하였으나 이 또한 발작빈도에 영양을 주지 않았다. 이 환자에
서 KCNT1 결실 돌연변이가 있음을 유전자 검사를 통하여 확인하여 
이에 대한 표적치료로 퀴니딘을 사용하였으며 발작빈도에 미미한 영
향을 주었으나 진전등의 부작용이 발생하여 사용을 중단하였다. 현재 
약물 복용을 지속하며 간헐적으로 직장으로 diazepam을 주입하여 
경련을 조절 중이다. 영아이동성 부분 발작 뇌전증에서 퀴니딘의 치
료가 모든 환자에서 효과가 있지 않음을 확인하였으며 개개인에 맞춤
치료를 지향하기 위한 선행연구가 필요할 것으로 생각된다.
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